Skip to main content

Myomo, Inc.

corporate_fare Company Profile

Myomo, Inc.

MYO·NYSE·Industrial Applications And Services·CIK 0001369290

Myomo, Inc. is a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. It develops and markets the MyoPro product line. A MyoPro is a myoelectric-controlled upper limb brace, or orthosis—a rigid brace used to support a patient's weak or paralyzed arm to enable and help improve functional activities of daily living, or ADLs, in the home and community. Each device is custom-fabricated by trained professionals during a custom fabrication process for each individual user to meet their specific needs. The products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. Myomo primarily provides devices directly to patients and bills their insurance companies directly, a sales channel it refers to as direct billing. Under direct billing, the company evaluates, measures and fits the MyoPro devices using its own clinical staff or, as circumstances dictate, utilizes the clinical consulting services of orthotics and prosthetics, or O&P. It also sells its products through various other sales channels, including through O&P providers, which it expects to be a larger contributor to revenue in the future, the Veterans Administration, or VA, and to certain accounts and geographic markets outside the United States. The company operates as one business segment. The MyoPro concept was originally pioneered in the 1960s, refined in the labs of the Massachusetts Institute of Technology, or MIT, and made commercially feasible through Myomo's efforts. The MyoPro is listed in the United States with the FDA as a Class II (510(k)-exempt) device (Biofeedback Device).

Myomo, Inc. (NYSE:MYO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 2 items for MYO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 7/10. Recent SEC coverage for MYO spans 10-Q, 8-K.

Recent high-impact activity:

  • Myomo 10-Q: Record $12.3M Q3 Revenue, 71.3% Gross Margin, $11.9M Cash
  • Myomo Posts Record $12.3M Q3 Revenue, Breakeven Adjusted EBITDA, Narrows FY Guidance to $46-47M

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$40.93M
Net Income
-$15.57M
Diluted EPS
-$0.37
Op. Cash Flow
-$14.51M
Free Cash Flow
-$16.25M
Gross Profit
$26.89M
Operating Income
-$14.4M
Cash & Equivalents
$14.13M
Total Debt
$14.18M
Debt / Equity
1.24×
Net Margin
-38.1%
Shares Outstanding
38.47M sh
Source: 10-K · filed 2026-04-29 · accession 0001193125-26-191496

Short Interest & Short Volume

5.75 days to cover

FINRA reported short interest of 1,156,175 shares in MYO as of the October 30, 2026 settlement, a 8.7% increase from the prior period — about 5.8 days to cover at its recent average daily volume. On November 19, 2026, 18.2% of MYO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,156,175 shares as of October 30, 2026
Change vs prior period▲ 8.7%
Days to cover5.75 at avg daily volume of 201,201
Daily short volume (FINRA facilities)18.2% of 204,485 shares on November 19, 2026
5-day average short volume39.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.8011 -4.63% today
52-week range · as of 2026-11-09 $0.605 – $1.89
Market cap
$32.08M
Volume
338K (1.2× avg)
3-mo avg 275.9K
Live data · 2026-11-20 20:42 UTC · Market open

show_chartPrice Chart

Loading chart...

feed MYO - Latest Insights

MYO
Nov 09, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.39
Real-time Price: $0.8011 info
Change: -$0.5889 (-42%) info
Market Cap: $32.079M info
MYO
Nov 09, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.24
Real-time Price: $0.8011 info
Change: -$0.4389 (-35%) info
Market Cap: $32.079M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets